Association between health-related quality of life (HRQoL) and clinical outcomes in patients with advanced first-line (1L) renal cell carcinoma (aRCC): Exploratory analyses from CheckMate 9ER (CM 9ER)
ANNALS OF ONCOLOGY（2022）
Abstract
In the CM 9ER trial, nivolumab plus cabozantinib (N+C) was associated with both increased survival and improved HRQoL in 1L aRCC patients (pts) at 23.5 months follow-up when compared to sunitinib (S). We investigated the association between HRQoL and overall survival (OS) and progression-free survival (PFS).
MoreTranslated text
Key words
renal cell carcinoma,health-related health-related quality,clinical outcomes,first-line
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined